Argus
•
Mar 25, 2026
RCUS: Lowering target price to $21.00
Summary
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherap
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: Bristol-Myers Squibb Company
Apr 30, 2026
•
BMY
Analyst Report: AstraZeneca PLC
Apr 30, 2026
•
AZN
Analyst Report: Regeneron Pharmaceuticals, Inc.
Apr 30, 2026
•
REGN
APLS: What does Argus have to say about APLS?
Apr 29, 2026
•
APLS
